| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11060-016-2287-6 |
| P8608 | Fatcat ID | release_eefqy2yizzewlitzmqylu5ua5m |
| P698 | PubMed publication ID | 27844311 |
| P2093 | author name string | Jeffrey Raizer | |
| Marc Chamberlain | |||
| Shengyan Hong | |||
| Surasak Phuphanich | |||
| Rajesh Narwal | |||
| Robert Miday | |||
| Kevin Laubscher | |||
| Minal Nade | |||
| Paola Canelos | |||
| P2860 | cites work | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 |
| Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma | Q29617568 | ||
| CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. | Q30427255 | ||
| Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations | Q30885944 | ||
| Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma | Q33387009 | ||
| PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas | Q34164924 | ||
| A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors | Q34403375 | ||
| Rituximab monotherapy for patients with recurrent primary CNS lymphoma | Q34686155 | ||
| Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. | Q35608531 | ||
| Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. | Q37345320 | ||
| Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas | Q37435455 | ||
| Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier | Q37819809 | ||
| Platelet-derived growth factor in glioblastoma-driver or biomarker? | Q38262433 | ||
| Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer | Q39171073 | ||
| Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials | Q40789890 | ||
| Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide | Q43290402 | ||
| Salvage therapy with single agent bevacizumab for recurrent glioblastoma. | Q45931836 | ||
| Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group | Q48271471 | ||
| Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors | Q48445033 | ||
| Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops | Q48478557 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 185-191 | |
| P577 | publication date | 2016-11-14 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma | |
| P478 | volume | 131 |
| Q57111067 | Glioblastoma Treatments: An Account of Recent Industrial Developments |
| Q100959515 | Novel guanidine compounds inhibit platelet-derived growth factor receptor alpha transcription and oligodendrocyte precursor cell proliferation |
| Q57291853 | Targeted Theranostic Nanoparticles for Brain Tumor Treatment |
Search more.